News Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Real-time Estimate Cboe Europe Other stock markets 10:17:36 2024-04-24 am EDT			5-day change	1st Jan Change
239.5 ^CHF	-4.28%		+0.67%	-8.57%

08:14am	Correction to Roche Article	DJ
07:50am	Roche Sales Decline on Currency Hit	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Correction to Roche Article	02:14am	DJ
Roche Sales Decline on Currency Hit	01:50am	DJ
Swiss Drugmaker Roche's Q1 Sales Fall; FY24 Outlook Confirmed	01:18am	MT
Roche Q1 sales down 6% on forex effect, loss of COVID revenue	01:10am	RE
Roche Holding AG Reports Sales Results for the First Quarter Ended March 2024	01:00am	CI
Roche Holding AG Provides Earnings Guidance for the Year 2024	01:00am	CI
EMEA Morning Briefing: Shares May Rise as Investors Brace for Earnings	12:18am	DJ
Swiss Equities Flash Green; Middle East Tensions Rise	Apr. 19	MT
Roche: approval in lung cancer in the United States	Apr. 19	CF
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	Apr. 19	MT
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval	Apr. 19	DJ
Roche's Early-stage Lung Cancer Treatment Alecensa Wins US FDA Nod	Apr. 19	MT
FDA Approves Roche?s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer	Apr. 19	CI
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	Apr. 18	BU
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment	Apr. 18	DJ
ROCHE HOLDINGS AG : UBS sticks Neutral	Apr. 18	ZD
Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial	Apr. 17	MT
Roche: positive phase III results in MS	Apr. 17	CF
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	Apr. 17	BU
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)	Apr. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : Q4 miss weighed heavily on the healthy 2024 guidance

February 01, 2024 at 07:42 am EST

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST